Cargando…

Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers

BACKGROUND: Recent studies reveal an association between slow-wave sleep (SWS), amyloid-β aggregation, and cognition. OBJECTIVE: This retrospective study examines whether long-term use of trazodone, an SWS enhancer, is associated with delayed cognitive decline. METHODS: We identified 25 regular traz...

Descripción completa

Detalles Bibliográficos
Autores principales: La, Alice L., Walsh, Christine M., Neylan, Thomas C., Vossel, Keith A., Yaffe, Kristine, Krystal, Andrew D., Miller, Bruce L., Karageorgiou, Elissaios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398835/
https://www.ncbi.nlm.nih.gov/pubmed/30689583
http://dx.doi.org/10.3233/JAD-181145
_version_ 1783399650178367488
author La, Alice L.
Walsh, Christine M.
Neylan, Thomas C.
Vossel, Keith A.
Yaffe, Kristine
Krystal, Andrew D.
Miller, Bruce L.
Karageorgiou, Elissaios
author_facet La, Alice L.
Walsh, Christine M.
Neylan, Thomas C.
Vossel, Keith A.
Yaffe, Kristine
Krystal, Andrew D.
Miller, Bruce L.
Karageorgiou, Elissaios
author_sort La, Alice L.
collection PubMed
description BACKGROUND: Recent studies reveal an association between slow-wave sleep (SWS), amyloid-β aggregation, and cognition. OBJECTIVE: This retrospective study examines whether long-term use of trazodone, an SWS enhancer, is associated with delayed cognitive decline. METHODS: We identified 25 regular trazodone users (mean age 75.4±7.5; 9 women, 16 men) who carried a diagnosis of Alzheimer’s dementia, mild cognitive impairment, or normal cognition, and 25 propensity-matched trazodone non-users (mean age 74.5±8.0; 13 women, 12 men), accounting for age, sex, education, type of sleep deficit (hypersomnia, insomnia, parasomnia), diagnosis, and baseline Mini-Mental State Examination (MMSE). Longitudinal group differences in cognitive testing were evaluated through repeated measures tests over an average inter-evaluation interval of four years. RESULTS: Trazodone non-users had 2.6-fold faster decline MMSE (primary outcome) compared to trazodone users, 0.27 (95% confidence interval [CI]: 0.07–0.48) versus 0.70 (95% CI: 0.50–0.90) points per year (p = 0.023). The observed effects were especially associated with subjective improvement of sleep complaints in post-hoc analyses (p = 0.0006). Secondary outcomes of other cognitive and functional scores had variable worsening in non-users and varied in significance when accounting for co-administered medications and multiple comparisons. Trazodone effects on MMSE remained significant within participants with AD-predicted pathology, with 2.4-fold faster decline in non-users (p = 0.038). CONCLUSIONS: These results suggest an association between trazodone use and delayed cognitive decline, adding support for a potentially attractive and cost-effective intervention in dementia. Whether the observed relationship of trazodone to cognitive function is causal or an indirect marker of other effects, such as treated sleep disruption, and if such effects are mediated through SWS enhancement requires confirmation through prospective studies.
format Online
Article
Text
id pubmed-6398835
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-63988352019-03-06 Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers La, Alice L. Walsh, Christine M. Neylan, Thomas C. Vossel, Keith A. Yaffe, Kristine Krystal, Andrew D. Miller, Bruce L. Karageorgiou, Elissaios J Alzheimers Dis Research Article BACKGROUND: Recent studies reveal an association between slow-wave sleep (SWS), amyloid-β aggregation, and cognition. OBJECTIVE: This retrospective study examines whether long-term use of trazodone, an SWS enhancer, is associated with delayed cognitive decline. METHODS: We identified 25 regular trazodone users (mean age 75.4±7.5; 9 women, 16 men) who carried a diagnosis of Alzheimer’s dementia, mild cognitive impairment, or normal cognition, and 25 propensity-matched trazodone non-users (mean age 74.5±8.0; 13 women, 12 men), accounting for age, sex, education, type of sleep deficit (hypersomnia, insomnia, parasomnia), diagnosis, and baseline Mini-Mental State Examination (MMSE). Longitudinal group differences in cognitive testing were evaluated through repeated measures tests over an average inter-evaluation interval of four years. RESULTS: Trazodone non-users had 2.6-fold faster decline MMSE (primary outcome) compared to trazodone users, 0.27 (95% confidence interval [CI]: 0.07–0.48) versus 0.70 (95% CI: 0.50–0.90) points per year (p = 0.023). The observed effects were especially associated with subjective improvement of sleep complaints in post-hoc analyses (p = 0.0006). Secondary outcomes of other cognitive and functional scores had variable worsening in non-users and varied in significance when accounting for co-administered medications and multiple comparisons. Trazodone effects on MMSE remained significant within participants with AD-predicted pathology, with 2.4-fold faster decline in non-users (p = 0.038). CONCLUSIONS: These results suggest an association between trazodone use and delayed cognitive decline, adding support for a potentially attractive and cost-effective intervention in dementia. Whether the observed relationship of trazodone to cognitive function is causal or an indirect marker of other effects, such as treated sleep disruption, and if such effects are mediated through SWS enhancement requires confirmation through prospective studies. IOS Press 2019-02-12 /pmc/articles/PMC6398835/ /pubmed/30689583 http://dx.doi.org/10.3233/JAD-181145 Text en © 2019 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
La, Alice L.
Walsh, Christine M.
Neylan, Thomas C.
Vossel, Keith A.
Yaffe, Kristine
Krystal, Andrew D.
Miller, Bruce L.
Karageorgiou, Elissaios
Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers
title Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers
title_full Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers
title_fullStr Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers
title_full_unstemmed Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers
title_short Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers
title_sort long-term trazodone use and cognition: a potential therapeutic role for slow-wave sleep enhancers
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398835/
https://www.ncbi.nlm.nih.gov/pubmed/30689583
http://dx.doi.org/10.3233/JAD-181145
work_keys_str_mv AT laalicel longtermtrazodoneuseandcognitionapotentialtherapeuticroleforslowwavesleepenhancers
AT walshchristinem longtermtrazodoneuseandcognitionapotentialtherapeuticroleforslowwavesleepenhancers
AT neylanthomasc longtermtrazodoneuseandcognitionapotentialtherapeuticroleforslowwavesleepenhancers
AT vosselkeitha longtermtrazodoneuseandcognitionapotentialtherapeuticroleforslowwavesleepenhancers
AT yaffekristine longtermtrazodoneuseandcognitionapotentialtherapeuticroleforslowwavesleepenhancers
AT krystalandrewd longtermtrazodoneuseandcognitionapotentialtherapeuticroleforslowwavesleepenhancers
AT millerbrucel longtermtrazodoneuseandcognitionapotentialtherapeuticroleforslowwavesleepenhancers
AT karageorgiouelissaios longtermtrazodoneuseandcognitionapotentialtherapeuticroleforslowwavesleepenhancers